NCT04648046View on ClinicalTrials.gov

CAR-T Cells for HIV Infection

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions
HIV Infections
Interventions
DRUG

Cyclophosphamide

Non-ablative conditioning with cyclophosphamide.

BIOLOGICAL

LVgp120duoCAR-T cells, low dose

A single dose of 3 x 10\^5 cells/kg LVgp120duoCAR-T cells will be infused.

BIOLOGICAL

LVgp120duoCAR-T cells, high dose

A single dose of 1 x 10\^6 cells/kg LVgp120duoCAR-T cells will be infused.

OTHER

Analytic Treatment Interruption

HIV antiretroviral therapy medications will be paused.

Trial Locations (2)

94110

RECRUITING

Zuckerberg San Francisco General, San Francisco

95817

RECRUITING

University of California, Davis, Sacramento

All Listed Sponsors
collaborator

Caring Cross

UNKNOWN

lead

Steven Deeks

OTHER